News LifeArc spends Keytruda cash on R&D ignored by pharma Formerly known as MRC Technology, charity to spend Keytruda royalties on R&D considered too risky by big pharma
News BenevolentAI to power small molecule drug discovery Deal with MRCT will look for potential new drug targets and candidates.
News AstraZeneca and MRC to create new centre for early drug disc... AstraZeneca and the UK's Medical Research Council have unveiled a groundbreaking collaboration which will see them working hand-in-hand in a joint research facility in Cambridge in the UK.<
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
